NEW YORK (GenomeWeb) – Cancer Genetics has received CE marking for its DNA probe-based in vitro diagnostic cervical cancer screening test, the company said today.

The CE mark, which shows a product is in compliance with European Union safety laws, will enable the company to market the FISH-based HPV-associated Cancer Test (FHACT) freely in the European Economic Area, which includes the EU member states and the European Free Trade Association, or 31 nations in all.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.